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High-Level Pan-Azole-Resistant Aspergillosis
Jakko van Ingen, Henrich A. L. van der Lee, Antonius J. M. M. Rijs, Eveline Snelders, Willem J. G. Melchers, Paul E. Verweij
Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
High-level pan-azole-resistant Aspergillus fumigatus was recovered from four patients with chronic lung disease. In one patient,
the development of progressive resistance followed long-term azole therapy and switching between antifungal azoles. The high-
level pan-azole-resistant phenotypes were not associated with a specific cyp51A gene mutation. New strategies that avoid the de-
velopment of progressive azole resistance are needed.
Azole resistance in Aspergillus fumigatus is an emerging prob-lemwhich is associatedwith treatment failure in patients with
aspergillus diseases (1). Resistance is commonly due to mutations
in the cyp51A gene (1) that typically lead to high-level resistance
(MIC, 8 mg/liter) against one azole and low-level resistance
(MICs close to the resistance breakpoint) against others (2, 3).
We identified four A. fumigatus isolates with MIC of 8 mg/
liter for all mold-active azoles, measured using EUCASTmethod-
ology (4). We labeled this unique phenotype high-level pan-azole
resistance. We analyzed the cyp51A gene sequence of the isolates,
using previously published algorithms (5), and retrieved clinical
data for these four patients (Table 1).
The first patient was a 22-year-oldmale with cystic fibrosis. After
being diagnosed with allergic bronchopulmonary aspergillosis
(ABPA), he commenced itraconazole and steroidmaintenance ther-
apy. Fungal sputum cultures after 8 months of itraconazole therapy
revealed an A. fumigatus isolate with the high-level pan-azole-re-
sistant phenotype. The patient continued itraconazole mainte-
nance therapy, and the high-level pan-azole-resistant isolate was
not recovered from repeat cultures.
The second patient was a 71-year-old male with a medical his-
tory of asthma, bronchiectasis, and intermittent culture positivity
with itraconazole- and voriconazole-susceptibleA. fumigatus. The
patient did not meet diagnostic criteria for ABPA and was never
treated with azoles. The high-level pan-azole-resistant A. fumiga-
tus isolate was isolated once from a sputum sample; follow-up
sputum cultures yielded azole-susceptible A. fumigatus.
The thirdpatientwas a 47-year-old femalewith severepulmonary
sarcoidosis, complicatedbyapneumothoraxwith subsequentpleural
empyema. From this empyema, an azole-susceptible A. fumigatus
isolate was cultured (itraconazole and voriconazoleMICs, 0.5mg/
liter; posaconazole MIC, 0.063 mg/liter). Treatment with itra-
conazole was started, later changed to voriconazole, and ulti-
mately changed to posaconazole as a chronic suppressive therapy.
After 18months of azole therapy, the patient’s disease progressed,
and a sputum sample was ordered for fungal culture. This sample
grew the high-level pan-azole-resistant isolate and induced a
switch to liposomal amphotericin B therapy. Despite treatment,
the patient’s condition deteriorated, and she died of respiratory
failure.
The fourth patient was a 39-year-old male diagnosed with
chronic granulomatous disease and ABPA. The patient had been
treated for multiple episodes of invasive pulmonary aspergillosis,
and he received secondary prophylaxis with itraconazole. He then
presentedwith arthritis of the sternoclavicular joint, and itracona-
zole-resistant A. fumigatus was cultured from biopsy specimens.
Treatment with voriconazole was initiated, but visual distur-
bances forced a switch to liposomal amphotericin B and anidula-
fungin. The patient responded and was discharged on posacona-
zole maintenance therapy. After 11 months, the patient presented
with increasing dyspnea, dry cough, and fever. A chest computed
tomography (CT) scan revealed a cavity and bronchiolitis in the
right lower lobe. Bronchoalveolar lavage cultures were positive for
A. fumigatus, which exhibited the high-level pan-azole-resistant
phenotype and anM220Rmutation in the cyp51A gene, absent in
the patient’s previous isolates. Micafungin was added to po-
saconazole, based on susceptibility test results (Table 1). After 1
and 7 days of treatment, follow-up cultures remained positive for
the high-level pan-azole-resistant strain. After 10 days of therapy,
the patient died of pulmonary hemorrhage. Microsatellite typing
(4) showed that the isolates from this patient were isogenic.
The isolates cultured from these four patients reveal a new and
highly worrisome phenotype characterized by high-level resis-
tance to allmold-active azoles, including the new azole isavucona-
zole. Isavuconazole was shown to exhibit cross-resistance to vori-
conazole (6). All patients had chronic lung diseases, and a chronic
aspergillus disease was diagnosed in three patients. In patients 1
and 2, there were no clinical factors that might explain the single
recovery of the high-level pan-azole-resistant A. fumigatus iso-
lates. The high-level pan-azole-resistant isolates might have been
acquired as such from the environment (7).
In patient 3, a persisting aspergillus infection was treated with
various antifungal azoles. Although the initial isolate was azole
susceptible, the high-level pan-azole-resistant isolate with an en-
vironmental resistancemechanism (TR46/Y121F/T289A)was cul-
tured during therapy. The high-level pan-azole-resistant pheno-
type may have developed during azole therapy or may have been
acquired as such from the environment. Clear evidence for the
development of progressive resistance was present in patient 4. As
Received 23 February 2015 Returned for modification 23 March 2015
Accepted 16 April 2015
Accepted manuscript posted online 22 April 2015
Citation van Ingen J, van der Lee HAL, Rijs AJMM, Snelders E, Melchers WJG,
Verweij PE. 2015. High-level pan-azole-resistant aspergillosis. J Clin Microbiol
53:2343–2345. doi:10.1128/JCM.00502-15.
Editor: D. W. Warnock
Address correspondence to Paul E. Verweij, paul.verweij@radboudumc.nl.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00502-15
July 2015 Volume 53 Number 7 jcm.asm.org 2343Journal of Clinical Microbiology
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://jcm.asm.org/
D
ow
nloaded from
 
treatment was switched between the azole compounds,A. fumiga-
tus progressively developed resistance to each azole that was used
for treatment. Possibly, the cavitary lesions or other difficult-to-
reach sites with high fungal burdens facilitated the development of
resistance (8).
We were unable to detect genetic changes in the cyp51A gene
that paralleled the development of the high-level pan-azole-resis-
tant phenotype (Table 1). We did not find known azole resistance
mechanisms in the isolate of patient 2, indicating that non-
cyp51A-mediated resistance mechanisms may have emerged in
these isolates. Two isolates (of patients 1 and 3) harbored cyp51A
mutations that have been associated with environmental azole
exposure, TR34/L98H and TR46/Y121F/T289A (1, 4). In the Neth-
erlands, typical MICs of TR34/L98H isolates are16 mg/liter for
itraconazole, 4 to 8 mg/liter for voriconazole, and 1 mg/liter for
posaconazole, and those of TR46/Y121F/T298A isolates are 16
mg/liter for voriconazole, variable for itraconazole (1 to16 mg/
liter), and 0.5 to 1 mg/liter for posaconazole (2). The high-level
pan-azole-resistant phenotype, particularly the high posacona-
zoleMIC, suggests that these isolates have accumulated additional
non-cyp51A resistance mechanisms. These could include the re-
cently described overexpression of cyp51A, cyp51B, and the cdr1B
efflux pump; for these threemechanisms,MICs of8mg/liter for
itraconazole, 1 to 8 mg/liter for voriconazole, and 0.125 to 2 mg/
liter for posaconazole have beenmeasured (9–11). Based on these
reported phenotypes, particularly the low-level posaconazole re-
sistance, these mechanisms are unlikely responsible for the high-
level pan-azole-resistant phenotype observed in these four pa-
tients’ isolates.
The M220R mutation (in patient 4) has not been previously
reported, but M220K and M220T have been reported to lead to
itraconazoleMICs of8mg/liter but variableMICs for voricona-
zole (1 to 4 mg/liter) and posaconazole (0.5 to 8 mg/liter), so
may equal the phenotype seen in patient 4 (12).
High-level pan-azole resistance has consequences for patient
management. Dose escalation of voriconazole, (intravenous) po-
saconazole, and azole-echinocandin combination therapy may be
effective against low-level azole-resistantA. fumigatus (3, 13). In a
high-level pan-azole-resistant infection, dose escalation will be
inadequate and the efficacy of combination therapy, at best, un-
certain. The activity of amphotericin B and the echinocandins in
vitro remained unaffected. Liposomal amphotericin B has shown
good efficacy in a nonneutropenic murine model of acute azole-
resistant invasive aspergillosis (14).
Direct detection of resistance mutations in clinical samples is
increasingly studied (15, 16). These samples indicated a wild-type
cyp51A gene or the M220R, TR34/L98H, or TR46/Y121F/T289A
resistance mechanism, none of which corresponds to the high-
level pan-azole resistance phenotype observed in these four pa-
tients.
We report the emergence of high-level pan-azole-resistant A.
fumigatus isolates. This phenotype might originate from the envi-
ronment but also may develop through switching between azole
compounds in patients with chronic aspergillosis. There is a clear
need to develop strategies in patients at risk for chronic aspergil-
losis that avoids high-level resistance development.
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